Trippbio, Inc.

Probenecid, a Gout Medication, Shows Promise as Broad-Spectrum Antiviral Against COVID-19 and Other Respiratory Viruses

- A new study indicates that probenecid, an FDA-approved drug for gout, exhibits broad antiviral properties against SARS-CoV-2, RSV, and influenza viruses. - Probenecid functions by blocking viral replication within cells, demonstrating effectiveness as both a prophylactic and post-exposure treatment in animal models. - Current COVID-19 treatments like remdesivir and monoclonal antibodies are expensive and require IV administration, whereas probenecid is an accessible oral medication. - Clinical trials are planned to determine optimal dosages, with potential for probenecid to enhance the efficacy of other antiviral treatments.